TCGA-39-5034-01A-01R-1443-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MTORC1_SIGNALING+0.450
- PROTEIN_SECRETION+0.430
- E2F_TARGETS+0.410
- G2M_CHECKPOINT+0.410
- UNFOLDED_PROTEIN_RESPONSE+0.380
- ANDROGEN_RESPONSE+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340
- MYC_TARGETS_V1+0.330
- OXIDATIVE_PHOSPHORYLATION+0.320
- ADIPOGENESIS+0.290
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.380
- IL6_JAK_STAT3_SIGNALING-0.360
- WNT_BETA_CATENIN_SIGNALING-0.270
- INFLAMMATORY_RESPONSE-0.250
- INTERFERON_GAMMA_RESPONSE-0.240
- P53_PATHWAY-0.190
- ALLOGRAFT_REJECTION-0.170
- KRAS_SIGNALING_DN-0.160
- TNFA_SIGNALING_VIA_NFKB-0.130
- APICAL_JUNCTION-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG778 | — | — | 0.857 |
| 2 | R265 | — | — | 0.838 |
| 3 | TCGA-78-7154-01A-11R-2039-07 | — | cohortA4 | 0.829 |
| 4 | TCGA-D8-A1XJ-01A-11R-A14M-07 | — | C | 0.819 |
| 5 | TCGA-UY-A78L-01A-12R-A33J-07 | — | — | 0.798 |
| 6 | MNG1017 | — | — | 0.794 |
| 7 | TCGA-78-7150-01A-21R-2039-07 | — | cohortA4 | 0.788 |
| 8 | C3L-00081 | — | cohortSQ2 | 0.787 |
| 9 | TCGA-AC-A23H-01A-11R-A157-07 | — | C | 0.777 |
| 10 | TCGA-34-5240-01A-01R-1443-07 | — | cohortSQ2 | 0.775 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MTORC1_SIGNALING | 0.450 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.290 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |